Kenya is among the first nine African countries selected to launch a groundbreaking injectable HIV prevention medication, Lenacapavir, by January 2026.
This was announced by Health Cabinet Secretary Aden Duale, affirming that Kenya will be among the countries to launch the twice-yearly injection alongside Eswatini, Lesotho, Mozambique, Nigeria, South Africa, Uganda, Zambia, and Zimbabwe.
The introduction of Lenacapavir is a big leap in the fight against HIV, particularly in sub-Saharan Africa, which still bears the highest burden of new infections.
Lenacapavir is the first and only injectable PrEP to be awarded the U.S. Food and Drug Administration (FDA) approval that offers six months’ protection in a single dose. The World Health Organization (WHO) added the drug to its new HIV prevention guidelines issued in July 2025, paving the way for global uptake.
“This milestone underscores our collective determination to expand access to effective, discreet, and sustainable prevention options across the region,” said CS Duale.
“There is an urgency for impactful and tailored solutions.”
Lenacapavir presents a game-changing alternative to daily oral PrEP by tackling two major hurdles that have limited its uptake adherence and stigma, especially among vulnerable groups.
The Ministry of Health says an implementation plan is already underway. Developed through a broad consultative process with key stakeholders, the plan outlines how Lenacapavir will be integrated into Kenya’s existing HIV prevention framework. The national guidelines that will guide the scale-up of the drug are being finalized.
CS Duale reiterated the government’s commitment to HIV prevention choices that are accessible and inclusive.
He noted that the addition of Lenacapavir to Kenya’s HIV response strategy is proof of the broader national interest in equity, innovation, and community-led health solutions.
Its roll-out will be led by the Ministry of Health through the National AIDS and STI Control Programme (NASCOP), alongside a network of health organizations with active roles in HIV treatment and prevention.
